

Franco Maggiolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7080808/publications.pdf>

Version: 2024-02-01

50
papers

3,624
citations

201674

27
h-index

206112

48
g-index

50
all docs

50
docs citations

50
times ranked

3767
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort. Journal of the International Association of Providers of AIDS Care, 2022, 21, 232595822211018.	1.5	1
2	SARS-CoV-2 infection in persons living with HIV: A single center prospective cohort. Journal of Medical Virology, 2021, 93, 1145-1149.	5.0	35
3	Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial. Antiviral Therapy, 2021, 26, 135965352110422.	1.0	0
4	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNa cohort. Journal of the International AIDS Society, 2019, 22, e25227.	3.0	46
5	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, The, 2019, 393, 143-155.	13.7	265
6	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 2019, 70, 379-387.	3.7	109
7	Post-treatment controllers after treatment interruption in chronically HIV-infected patients. Aids, 2018, 32, 623-628.	2.2	18
8	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). International Journal of Epidemiology, 2017, 46, dyv192.	1.9	15
9	Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infectious Diseases, 2017, 17, 215.	2.9	76
10	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV, 2017, 4, e536-e546.	4.7	101
11	Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. Journal of Pragmatic and Observational Research, 2017, Volume 8, 91-97.	1.5	16
12	NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 46-51.	2.1	30
13	Abacavir + dolutegravir + lamivudine for the treatment of HIV. Expert Opinion on Pharmacotherapy, 2016, 17, 2097-2106.	1.8	11
14	The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study. Infectious Agents and Cancer, 2015, 10, 34.	2.6	5
15	Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 585-592.	2.1	9
16	Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Related Outcome Measures, 2015, 6, 53.	1.2	2
17	Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health, 2015, 15, 235.	2.9	29
18	Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. Journal of Infectious Diseases, 2014, 210, 354-362.	4.0	284

#	ARTICLE	IF	CITATIONS
19	Single-Tablet Regimens in HIV Therapy. <i>Infectious Diseases and Therapy</i> , 2014, 3, 1-17.	4.0	49
20	Dolutegravir plus Abacavir+Lamivudine for the Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 1807-1818.	27.0	697
21	Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 59.	1.9	24
22	Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAART-Treated Patients and Risk of Virological Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 473-482.	2.1	75
23	Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 111-118.	9.1	260
24	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	3.0	56
25	Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naïve patients. <i>Antiviral Therapy</i> , 2010, 15, 51-59.	1.0	21
26	One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. <i>Patient Preference and Adherence</i> , 2010, 4, 115.	1.8	130
27	Is HAART modifying the HIV epidemic?. <i>Lancet</i> , The, 2010, 376, 492-493.	13.7	14
28	Efavirenz: a decade of clinical experience in the treatment of HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 910-928.	3.0	106
29	CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. <i>Aids</i> , 2009, 23, 799-807.	2.2	40
30	Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Confering Mutations in NNRTI- or PI-Treated Patients. <i>HIV Clinical Trials</i> , 2007, 8, 282-292.	2.0	132
31	Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 569-572.	3.0	17
32	Efavirenz. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1137-1145.	1.8	20
33	Resistance Costs and Future Drug Options of Antiretroviral Therapies: Analysis of the Role of NRTIs, NNRTIs, and PIs in a Large Clinical Cohort. <i>HIV Clinical Trials</i> , 2007, 8, 9-18.	2.0	9
34	Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. <i>Aids</i> , 2007, 21, 2409-2415.	2.2	86
35	The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. <i>Antiviral Therapy</i> , 2006, 11, 923-9.	1.0	2
36	The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens. <i>Antiviral Therapy</i> , 2006, 11, 923-930.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Switch strategies in patients on effective HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 821-823.	3.0	13
38	Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 190-195.	3.0	35
39	Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors. <i>Clinical Infectious Diseases</i> , 2005, 40, 158-163.	5.8	205
40	Quadruple-Drug Induction HAART in Advanced HIV Infection. <i>HIV Clinical Trials</i> , 2005, 6, 1-4.	2.0	3
41	Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells. <i>Aids</i> , 2004, 18, 439-446.	2.2	114
42	Outcome of 2 Simplification Strategies for the Treatment of Human Immunodeficiency Virus Type 1 Infection. <i>Clinical Infectious Diseases</i> , 2003, 37, 41-49.	5.8	78
43	Once-a-Day HAART: Dream or Reality?. <i>HIV Clinical Trials</i> , 2003, 4, 193-201.	2.0	13
44	Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. <i>Antiviral Therapy</i> , 2003, 8, 121-6.	1.0	0
45	Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. <i>Antiviral Therapy</i> , 2003, 8, 339-46.	1.0	15
46	Once-A-Day Therapy for HIV Infection: A Controlled, Randomized Study in Antiretroviral-Naive HIV-1-Infected Patients. <i>Antiviral Therapy</i> , 2003, 8, 339-346.	1.0	49
47	Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. <i>HIV Clinical Trials</i> , 2002, 3, 52-57.	2.0	66
48	Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2002, 3, 371-378.	2.0	81
49	Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. <i>Blood</i> , 2002, 99, 4588-4591.	1.4	135
50	Duration of Viral Suppression in Patients on Stable Therapy for HIV-1 Infection Is Predicted by Plasma HIV RNA Level After 1 Month of Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 25, 36-43.	2.1	20